Le Laboratoire pré-analytique (LPA) soutient les chercheur-euses du CHUV et de la FBM en matière de biobanques.
Échantillons disponibles auprès de la Biobanque génomique du CHUV: plus de 40'000 patient-es adultes.
Elle assure le respect des directives légales et institutionnelles pour obtenir des données non cliniques issus de patient-es ou de collaborateur-trices du CHUV. Toute demande doit être soumise à la CEDE en respectant la procédure en vigueur. La procédure s’applique pour la conduite d’un projet, tel
We create predictive models that go beyond observation to simulate how biological systems respond to drug, genetic or immunotherapy perturbations, supporting virtual experimentation that accelerates hypothesis generation and therapeutic prioritization. In the Perturb theme, we develop AI/ML models t
We develop models that learn unified, multimodal representations of biological systems, integrating diverse data types — from single-cell and spatial omics to histopathology imaging — so that heterogeneous cellular states, tissue morphology and spatial architecture are jointly captured. In the Repre
We build explainable AI methods that uncover the biological and spatial drivers behind AI model predictions, enabling discovery of biological mechanisms, and spatial biomarkers that can be pursued for validation and therapeutic targeting. In the Interpret theme, we develop AI methods that provide ex
CHORUS, a secure processing environment developed at CHUV, enables reliable sharing of biomedical data and collaboration among research teams. By combining advanced encryption with rigorous authentication protocols, CHORUS promotes biomedical innovation while protecting sensitive patient information
We evaluate genotyping versus low-coverage whole-genome sequencing for detecting variants in pharmacogenes, to identify the most reliable method for clinical use and inform standardized genome-based protocols to prevent adverse drug reactions. This research project aims to advance personalized medic
This project aims to develop a comprehensive prediction model for chronic kidney disease by integrating classical risk factors with inherited and acquired genetic data. To do so we will use the cutting-edge Blended Genome–Exome sequencing technology on DNA samples from the Swiss HIV Cohort Study, as
An international project aiming to establish the role of germline DNA variation in determining the efficacy and toxicity of cancer immunotherapy. We analyze the DNA of patients undergoing immunotherapy to identify biomarkers that can help predict the efficacy and toxicity of these treatments. An imp